Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Canaccord Genuity Stick to Their Buy Rating for Teladoc

Published 02/25/2021, 06:37 AM
Updated 02/25/2021, 06:37 AM


Canaccord Genuity analyst Richard Close maintained a Buy rating on Teladoc (NYSE:TDOC) on Wednesday, setting a price target of $330, which is approximately 29.65% above the present share price of $254.53.

Close expects Teladoc to post earnings per share (EPS) of -$0.43 for the first quarter of 2021.

The current consensus among 16 TipRanks analysts is for a Moderate Buy rating of shares in Teladoc, with an average price target of $251.33.
The analysts price targets range from a high of $330 to a low of $200.

In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $288.81 million and a net profit of $5.67 million. The company's market cap is $36.9 billion.

According to TipRanks.com, Canaccord Genuity analyst Richard Close is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 31.9% and a 62.65% success rate.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002 by George Byron Brooks and is headquartered in Purchase, NY.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.